| Ytd | 26.97% | |
| 1y | 57.82% |
| Open | 23.21 | Prev Close | 23.47 | Low | 21.90 | High | 23.02 | Mkt Cap | 886.87M |
| Vol | 484.40K | Avg Vol | 561.01K | EPS | -2.31 | P/E | N/A | Forward P/E | -7.78 |
| Beta | 1.16 | Short Ratio | 8.92 | Inst. Own | 87.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 28.51 | 200-d Avg | 24.23 | 1yr Est | 38.38 |
ANRO News
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alto Neuroscience (NYSE:ANRO) with
Alto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300
Alto Neuroscience, Inc. (âAltoâ) (NYSE: ANRO), a clinical-stage biopharmaceutical company focuse
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) have received a consensus rating of
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel pr
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clini
AWM Investment Company Inc. bought a new position in shares of Alto Neuroscience, Inc. (NYSE: ANRO)
Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s share price hit a new 52-week high during m
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alto Neuroscience (NYSE:ANRO) with
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the
BTIG analyst Thomas Shrader maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the pri
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.65) per share which beat the analyst
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) have earned a consensus recommendat
Alto Neuroscience maintains a 'Buy' rating, driven by the potential of ALTO-207 for treatment-resist
Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company wit
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
On July 13, 2026, Alto Neuroscience, Inc. (the "Company") announced that, based upon prelimi
Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
Alto Neuroscience, Inc. (âAltoâ) (NYSE: ANRO), a clinical-stage biopharmaceutical company focuse
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clini
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.80) per share which missed the analys
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO)
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with
Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clini
— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole m
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clini
6,000,000 SharesCommon Stock Offered by the Selling StockholdersThis prospectus relates to the propo
Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s share price gapped down before the market o
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers
US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Q
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with
Jones Trading analyst Justin Walsh maintains Alto Neuroscience (NYSE:ANRO) with a Buy and lowers
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and lowers the
Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other s
Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo
— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoi
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and raises
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the
– Financing led by Commodore Capital with participation from new and existing biotech focused invest
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.45) per share which beat the analyst